Business & Industry

GSK’s new chief executive, Luke Miels, said the drugmaker will prioritise faster drug development as it enters its next phase of growth, with a tighter focus on programmes that can change standards of care and selective bolt-on acquisitions. Miels,...

Examination of the pharmaceutical industry's transition toward biodegradable polymers and eco-friendly excipients to reduce environmental impact while maintaining high therapeutic standards.

The UK and Japanese governments have announced a wide-ranging partnership that sees UK and Japan strengthen science and technology ties across pharmaceuticals, genomics, quantum computing and advanced manufacturing. The agreement was confirmed during a visit to Japan by the...

Halo Pharma becomes dedicated North American drug product CDMO after emerging as a standalone contract development and manufacturing organization focused exclusively on drug product services in North America. The transition follows SK Capital Partners’ decision to divest the active...

Drugmakers turn to AI as a practical way to reduce delays in clinical trials and regulatory submissions, even as artificial intelligence has yet to consistently deliver breakthrough drug molecules, industry executives said at the JP Morgan Healthcare Conference. Executives from...

Seamless Therapeutics has entered a global research collaboration and licensing agreement with Eli Lilly and Company under the Seamless Therapeutics Eli Lilly hearing loss collaboration, focused on developing programmable recombinase-based genetic medicines for hearing loss. The collaboration will unite Seamless...

AstraZeneca has agreed to license experimental obesity and metabolic disease drugs from China’s CSPC Pharmaceutical Group under the AstraZeneca CSPC weight-loss deal, with total potential payments reaching $18.5 billion. The agreement includes $1.2 billion paid upfront, with up to $17.3...